First clinical experience with CDK4/6 inhibitors in breast cancer therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

First clinical experience with CDK4/6 inhibitors in breast cancer therapy

Published:2021-03-22 Issue:5 Volume:21 Page:
ISSN:1792-0981
Container-title:Experimental and Therapeutic Medicine
language:
Short-container-title:Exp Ther Med

Author:

Cobec Ionut¹,Moleriu Lavinia²,Moatar Aurica³,Rempen Andreas¹

Affiliation:

1. Clinic of Obstetrics and Gynecology, Diakonie‑Klinikum Schwäbisch Hall, D‑74523 Schwäbisch Hall, Germany

2. Department of Medical Informatics and Biostatistics, ‘Victor Babeș’ University of Medicine and Pharmacy, Timișoara, 300041 Timișoara, Romania

3. Clinic of Internal Medicine, Hohenloher Krankenhaus Öhringen, D‑74613 Öhringen, Germany

Publisher

Spandidos Publications

Subject

Cancer Research,Immunology and Microbiology (miscellaneous),General Medicine

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Observational Study of Men and Women with Breast Cancer in Terms of Overall Survival;Cancers;2024-09-01

2. Triple-Negative Breast Cancer: Molecular Particularities Still a Challenge;Diagnostics;2024-08-27

3. The Influence of Tumor-Specific Markers in Breast Cancer on Other Blood Parameters;Life;2024-03-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP